Can-Fite BioPharma (CANF) Current Deferred Revenue (2016 - 2025)
Can-Fite BioPharma's (CANF) quarterly Current Deferred Revenue came in at $1.6 million in Q4 2025, down 20.39% YoY from $2.0 million in Q4 2024, and down 11.58% on a QoQ basis from $1.8 million in Q2 2025.
Can-Fite BioPharma (CANF) Current Deferred Revenue (2016 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 10 years of Current Deferred Revenue data on file, last reported at $1.6 million in Q4 2025.
- Quarterly Current Deferred Revenue fell 20.39% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (down 20.39% YoY) and the FY2025 annual result came in at $1.6 million, down 20.39% from the prior year.
- Current Deferred Revenue eased to $1.6 million in Q4 2025, from $1.8 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $3.1 million in Q4 2022 to a low of $783000.0 in Q2 2023.
- A 5-year average of $1.6 million and a median of $1.7 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue jumped 276.28% — and 2023, when it declined 24.14%.
- Tracing CANF's Current Deferred Revenue over 5 years: stood at $818000.0 in 2021, then jumped by 276.28% to $3.1 million in 2022, then fell by 24.14% to $2.3 million in 2023, then dropped by 14.95% to $2.0 million in 2024, then fell by 20.39% to $1.6 million in 2025.
- The last three Current Deferred Revenue figures came in at $1.6 million (Q4 2025), $1.8 million (Q2 2025), and $2.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Jun 30, 2023 | 783,000.00 |
| Dec 31, 2022 | 3.08 Mn |
| Jun 30, 2022 | 818,000.00 |
| Dec 31, 2021 | 818,000.00 |
| Jun 30, 2021 | 1.00 Mn |
| Dec 31, 2020 | 334,000.00 |
| Jun 30, 2020 | 556,000.00 |
| Dec 31, 2019 | 469,000.00 |
| Jun 30, 2019 | 1.96 Mn |
| Dec 31, 2018 | 926,000.00 |
| Jun 30, 2018 | 792,000.00 |
| Dec 31, 2017 | 330,000.00 |
| Dec 31, 2016 | 322,000.00 |